Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes

被引：0
|
作者：
Dreesen, E. [1 ]
Laharie, D. [2 ]
Lambrecht, G. [3 ]
Bossuyt, P. [4 ]
Buisson, A. [5 ]
Filippi, J. [6 ]
Van Hootegem, P. [7 ]
D'Haens, G. [8 ]
Vermeire, S. [9 ,10 ]
Gils, A. [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Hosp Haut Leveque, Bordeaux, France
[3] Damiaan Hosp, Oostende, Belgium
[4] Imelda Hosp, Bonheiden, Belgium
[5] Hosp Estaing, Clermont Ferrand, France
[6] Hosp Archet, Nice, France
[7] Sint Lucas Hosp, Brugge, Belgium
[8] Acad Med Ctr, Amsterdam, Netherlands
[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P572
引用
收藏
页码：S396 / S397
页数：3
相关论文
共 50 条
  • [31] Evidence of infliximab dose stability in Crohn's disease
    Cohen, R
    Farr, C
    Ziskind, M
    Tandon, N
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S228 - S228
  • [32] Durability of Infliximab Dose Intensification in Crohn's Disease
    Lin, Kirk K.
    Velayos, Fernando
    Fisher, Elena
    Terdiman, Jonathan P.
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (04) : 1013 - 1019
  • [33] Durability of Infliximab Dose Intensification in Crohn's Disease
    Lin, Kirk
    Terdiman, Jonathan E.
    GASTROENTEROLOGY, 2010, 138 (05) : S695 - S695
  • [34] Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
    Bultman, E.
    de Haar, C.
    van Liere-Baron, A.
    Verhoog, H.
    West, R. L.
    Kuipers, E. J.
    Zelinkova, Z.
    van der Woude, C. Janneke
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) : 335 - 341
  • [35] Recommendations for Dose Adjustments of Infliximab in Crohn's Disease Patients with Higher Clearance
    Andersson, Helena
    Eser, Akexander
    Huisinga, Wilhelm
    Reinisch, Walter
    Kloft, Charlotte
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S27 - S27
  • [36] Population pharmacokinetics of single dose infliximab in patients with Crohn's disease.
    Fasanmade, AA
    Zhu, YW
    Wagner, C
    Pendley, C
    Davis, HM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P66 - P66
  • [37] Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States
    Khalid, Javaria Mona
    Raluy-Callado, Mireia
    Li, Qian
    Luo, Michelle
    Lasch, Karen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S316 - S317
  • [38] Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels
    Allegretti, Jessica R.
    Carrellas, Madeline
    Hamilton, Matthew
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2016, 150 (04) : S421 - S421
  • [39] Desensitisation to infliximab in patients with Crohn's disease
    Lelong, J
    Duburque, C
    Fournier, C
    Colombel, JF
    Desreumaux, P
    Tonnel, AB
    Wallaert, B
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (02) : 239 - 246
  • [40] Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn's disease
    Demase, K.
    Smith, R. L.
    Luber, R.
    Taylor, K. M.
    Ward, M. G.
    Sparrow, M. P.
    Little, R. D.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1317 - I1317
12345